Sign inJoin waitlistJoin the waitlist

Clare Twist

Director of Pediatric Experimental Therapeutics · ROSWELL PARK CANCER INSTITUTE

Credentials: · · · ·

History

Pediatric Experimental Therapeutics · University at Buffalo School of Medicine
Present
ROSWELL PARK CANCER INSTITUTE
Present
University at Buffalo School of Medicine
Present

Research

Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease…
Blood · 1998 · 248 citations
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study
Journal of Clinical Oncology · 2010 · 227 citations
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology…
Clinical Cancer Research · 2006 · 134 citations

Julie Park
12 papers
Susan Cohn
11 papers
Katherine Matthay
8 papers
Araz Marachelian
7 papers
John Maris
7 papers
Rochelle Bagatell
7 papers
Hiroyuki Shimada
6 papers
Dita Gratzinger
5 papers
Meaghan Granger
5 papers
Brent Tan
4 papers
Carlos Esquivel
4 papers
Clifford Chin
4 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $10K · Stanford University
2004–2008
Regulation of Dendritic Cell-Lymphocyte Interactions
National Institute of Allergy and Infectious Diseases · K11
Contact PI · $429.6K · Dana-Farber Cancer Inst
1993–1999

Clinical trials

Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia
Principal investigator · Terminated · Phase 1
Clare Twist
2004–2008
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Study chair · Active not recruiting · Phase 1
Children's Oncology Group
2022–2027
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Study chair · Completed · Phase 3
Children's Oncology Group
2007–2021
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031